Communication Skills Intervention to Promote Transition Into Survivorship

Diffuse Large B-cell Lymphoma Clinical Trial

Official title:

Communication Skills Intervention to Promote Transition Into Survivorship

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01483664
• Other study ID #: 11-180
• Status: Active, not recruiting
• Start date: November 2011
• Est. completion date: November 2024

Study information

• Verified date: June 2023
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to improve the communication skills of physicians who transition lymphoma cancer patients from the end of treatment to survivorship.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 314
• Est. completion date: November 2024
• Est. primary completion date: November 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Physicians:

• who treat patients with DLBCL and HD as per self report

Patients of Physicians:

• have a new diagnosis of Hodgkin's or Diffuse Large B-cell Lymphoma as per pathology report or physician assessment in medical record and/or clinical judgment of the treating physician treated with curative intent.

For part 1 - have scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment.

For part 2 (longitudinal phase): - have new scans indicating remission and completing planned chemotherapy and/or radiation therapy. The treating physician will determine that clinical remission has been achieved based on their best judgment.

• be at least 18 years old

• speak English well enough, in the judgment of the consenting professional, to be able to understand all aspects of the study, provide informed consent, and be able to complete all study measures.

Exclusion Criteria:

Physicians:

• who do not have adequate patients in their clinical practice to meet the 8 patient enrollment requirement for patients with either DLBCL or HD as per self report

Patients of Physicians:

• show evidence of cognitive impairment severe enough to preclude giving permission to the study staff, or completing the survey instruments of the study.

• as per physician judgment, patient's prognosis and/or co-morbidities make them inappropriate for participation in a survivorship study.

For Part 2 ONLY (longitudinal phase):

• those who consented to part 1, consult recording, of the study.

Related Conditions & MeSH terms

• Diffuse Large B-cell Lymphoma
• Hodgkin's Lymphoma
• Lymphoma
• Lymphoma, Large B-Cell, Diffuse

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering at Basking Ridge	Basking Ridge	New Jersey
United States	Maimonides Medical Center	Brooklyn	New York
United States	Memorial Sloan Kettering Cancer Center at Commack	Commack	New York
United States	Md Anderson Cancer Center	Houston	Texas
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Memorial Sloan Kettering Cancer Center at Mercy	Rockville Centre	New York
United States	Memorial Sloan Kettering Cancer Center at Phelps	Sleepy Hollow	New York
United States	Moffitt Cancer Center	Tampa	Florida
United States	Tampa General Hospital	Tampa	Florida

Sponsors (12)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	H. Lee Moffitt Cancer Center and Research Institute, M.D. Anderson Cancer Center, Maimonides Medical Center, Monash University, National Cancer Institute (NCI), New York Presbyterian Brooklyn Methodist Hospital, Rutgers University, San Francisco State University, Tampa General Hospital, University of California, Los Angeles, Weill Cornell Medical College in Qatar

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	impact on patient outcomes of targeted physician communication skills training		3 years
Secondary	impact of a targeted CST intervention on the physicians	use of strategies, tasks and skills about transitioning lymphoma patients from the end of primary treatment to survivorship.	3 years
Secondary	describe communication during doctor-patient visits during the patients' first three years of survivorship	(MSKCC and MD Anderson baseline data only) The study team will look for qualitative themes to better understand the content of these conversations and the need for survivorship care planning. Half of these recordings were with MSKCC patients and physicians and half were with MD Anderson patients and physicians.	3 years

External Links

•   Memorial Sloan Kettering Cancer Center